Cost-Utility of Omalizumab Compared With Standard of Care for The Treatment of Chronic Spontaneous Urticaria (CSU)

Jonathan B. Graham; Donald Edgar Stull; Doreen Watson McBride; Jonathan B. Graham; Doreen Watson McBride; Donald Edgar Stull; A Halliday; ST Alexopoulos; Maria-Magdalena Balp; M Griffiths; I Agirrezabal; Brennan A

Cost-Utility of Omalizumab Compared With Standard of Care for The Treatment of Chronic Spontaneous Urticaria (CSU)

Graham, J., McBride, D., Stull, D., Halliday, A., Alexopoulos, ST., Balp, M., Griffiths, M., Agirrezabal, I., & Brennan A, U. (2015). Cost-Utility of Omalizumab Compared With Standard of Care for The Treatment of Chronic Spontaneous Urticaria (CSU). Value in Health, 18(7), A423. https://doi.org/10.1016/j.jval.2015.09.571

Copy citation

Recent Publications

Article

The early motor questionnaire facilitates the remote assessment of normative motor development in infancy and toddlerhood

January 01, 2025

Article

Cost-Utility of Omalizumab Compared With Standard of Care for The Treatment of Chronic Spontaneous Urticaria (CSU)

Recent Publications

The early motor questionnaire facilitates the remote assessment of normative motor development in infancy and toddlerhood

Adult vaccination coverage in the United States

Implementing law enforcement-based victim services

Dengue and diabetes comorbidity